{"sourcedb":"DevicePMAs@therightstef","sourceid":"P100031_S009","text":"Approval for the migration of claims from the fda approved elecsys anti-hbc immunoassay and elecsys precicontrol anti-hbc on the modular analytics e170 to the cobas e 602 immunoassay analyzer. the device, as modified, will be marketed under the tradename elecsys anti-hbc immunoassay and elecsys precicontrol anti-hbc and is indicated for: elecsys anti-hbc immunoassaythe elecsys anti-hbc immunoassay is intended for the in vitro qualitative determination of total antibodies to hepatitis b core antigen (anti-hbc) in human serum and plasma (lithium heparin, sodium citrate, k2-edta) in adult patients with the symptoms of hepatitis or whomay be at risk for hepatitis b virus (hbv) infection. the detection of total anti-hbc is indicative of a laboratory diagnosis for hbv infection. further hbv serological marker testing is required to define the specific disease state. the elecsys anti-hbc immunoassaysperformance has not been established for the monitoring of hbv disease or therapy. the electrochemiluminescence immunoassay eclia is intended for use on the modular analytics e170 and cobas e 602 immunoassay analyzers. elecsys precicontrol anti-hbc precicontrol anti hbc is used for quality control of the elecsys anti hbc immunoassay on the modular analytics e170 and cobas e 602 immunoassay analyzers.","project":"consensus_PMA_Age_Indications"}